Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant factor VIII + tranexamic acid
- Development stage
- Preclinical
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of recombinant Factor VIII (rFVIII) and tranexamic acid (TXA) used primarily in the treatment of hemophilia A. rFVIII replaces the missing clotting factor to initiate clot formation, while TXA inhibits fibrinolysis, thereby significantly improving clot stability. Studies have shown that this combination provides superior clot resistance to accelerated fibrinolysis compared to rFVIII alone, with potential benefits in both prophylactic settings and acute bleeding episodes.
02
Targets
F8 (Coagulation Factor VIIIa)PLG (Plasminogen)
Beyond the preview
Go deeper on recombinant factor VIII + tranexamic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant factor VIII + tranexamic acid.